TTI — Thiogenesis Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$30.56m
- CA$26.42m
- 38
- 11
- 57
- 27
Annual income statement for Thiogenesis Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 4.02 | 5.21 |
| Operating Profit | -4.02 | -5.21 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -3.92 | -5.06 |
| Net Income After Taxes | -3.92 | -5.06 |
| Net Income Before Extraordinary Items | ||
| Net Income | -3.92 | -5.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -3.92 | -5.06 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.076 | -0.129 |